TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes | Zendy

Nadine Tung | Zendy; Mark E. Robson | Zendy; Steffen Ventz | Zendy; Cesar A. SantaMaria | Zendy; Rita Nanda | Zendy; P. Kelly Marcom | Zendy; Payal D. Shah | Zendy; Tarah J. Ballinger | Zendy; Eddy S. Yang | Zendy; Shaveta Vinayak | Zendy; Michelle Melisko | Zendy; Adam Brufsky | Zendy; Michelle K. DeMeo | Zendy; C. David Jenkins | Zendy; Susan M. Domchek | Zendy; Alan D. D’Andrea | Zendy; Nancy U. Lin | Zendy; Melissa E. Hughes | Zendy; Lisa A. Carey | Zendy; Nick Wagle | Zendy; Gerburg M. Wulf | Zendy; Ian E. Krop | Zendy; Antonio C. Wolff | Zendy; Eric P. Winer | Zendy; Judy E. Garber | Zendy

Open Access

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes

Author(s) -

Nadine Tung,

Mark E. Robson,

Steffen Ventz,

Cesar A. SantaMaria,

Rita Nanda,

P. Kelly Marcom,

Payal D. Shah,

Tarah J. Ballinger,

Eddy S. Yang,

Shaveta Vinayak,

Michelle Melisko,

Adam Brufsky,

Michelle K. DeMeo,

C. David Jenkins,

Susan M. Domchek,

Alan D. D’Andrea,

Nancy U. Lin,

Melissa E. Hughes,

Lisa A. Carey,

Nick Wagle,

Gerburg M. Wulf,

Ian E. Krop,

Antonio C. Wolff,

Eric P. Winer,

Judy E. Garber

Publication year - 2020

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.20.02151

Subject(s) - olaparib , medicine , oncology , chek2 , metastatic breast cancer , palb2 , parp inhibitor , germline mutation , breast cancer , cohort , progression free survival , cancer , cancer research , mutation , chemotherapy , genetics , poly adp ribose polymerase , gene , biology , polymerase

Olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi), is approved for the treatment of human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) in germline (g) BRCA1 / 2 mutation carriers. Olaparib Expanded, an investigator-initiated, phase II study, assessed olaparib response in patients with MBC with somatic (s) BRCA1 / 2 mutations or g/s mutations in homologous recombination (HR)-related genes other than BRCA1/ 2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research